Time to cuddle up, it's National Hug Your Dog Day
GREENVILLE, N.C. (WNCT) — Grab your pups, it's National Hug Your Dog Day!
National Hug Your Dog Day falls on Wednesday, April 10. Research says that hugging your pet can release oxytocin. Oxytocin is known as the, 'cuddle hormone' according to National Today's website. By cuddling up with your dog you strengthen the bond between animal and human while reducing stress.
As a disclaimer, always pay attention to your dog's body language. Not all dogs are happy to be hugged and they tend to let you know by being tense, whining or even growling. If your dog is not much of a hugger try connecting with them in a different way, like belly rubs or play time.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
/C O R R E C T I O N -- Human Longevity, Inc./
In the news release, Human Longevity, Inc. Expands Pancreatic Cancer Prevention Commitment with $1 Million Pledge for Qualified Members, issued 17-Jun-2025 by Human Longevity, Inc. over PR Newswire, we are advised by the company that the media contact information should be added to the public distribution. The complete, corrected release follows: SOUTH SAN FRANCISCO, Calif., June 17, 2025 /PRNewswire/ -- Human Longevity, Inc. (HLI), a global leader in precision medicine and proactive health, today announced an expansion of its $1 million pledge initiative—this time targeting late-stage pancreatic cancer. Building on the success of its recent prostate cancer commitment, HLI is advancing its mission to detect cancer earlier and improve outcomes for its members by offering financial and clinical support for those members diagnosed with late-stage pancreatic cancer while enrolled in its Executive Health and 100+ Longevity programs. Driving Innovation in Early Detection Through its Executive Health Program and 100+ Longevity Programs, Human Longevity has delivered care to over 10,000 members using a comprehensive platform that integrates whole genome sequencing, advanced imaging, and multiplex blood biomarker tracking. These efforts have enabled the development of what HLI believes to be one of the most advanced early detection algorithms for pancreatic cancer available today, including a new proprietary DNA-based pancreatic cancer screening test. In most cases, our multi-modal screening approach helps detect cancer at a stage when it is curable. But in the rare event that a member is diagnosed at a late stage, our $1 million pledge ensures they receive the most advanced care available—without the burden of financial barriers. How the $1 Million Pledge Works Eligible individuals must be active pledge participants in HLI's Executive Health Program or affiliated Longevity Programs for pancreatic cancer early screening. These programs include: Whole genome sequencing Whole-body MRI, with dedicated pancreatic imaging Long-term blood biomarker analysis A DNA-based pancreatic cancer screening blood test Qualified members diagnosed with late-stage pancreatic cancer while under HLI's care will receive up to $1 million toward treatment, care coordination, and access to a network of top-tier oncology experts from leading medical institutions. Transforming the Future of Pancreatic Cancer Care Pancreatic cancer is one of the deadliest forms of cancer due to its lack of early symptoms and late detection. Human Longevity's initiative aims to shift this paradigm by detecting disease earlier—when it is most treatable. The pledge not only offers support to individuals but also accelerates advancements in cancer screening technology through continuous real-world data integration and machine learning. About Human Longevity, Inc. Human Longevity, Inc. is a pioneering biotechnology company at the forefront of genomics, AI, and advanced medical technologies to extend healthspan and revolutionize preventative care. By leveraging vast genomic data, metabolomics, advanced imaging, and AI-driven diagnostics, Human Longevity is transforming healthcare from disease management to proactive prevention through its Executive Health and other Longevity Programs. The company remains committed to advancing medical research, improving patient outcomes, and unlocking the full potential of genomics to address the world's most pressing health challenges. Media Contactmedia@ View original content to download multimedia: SOURCE Human Longevity, Inc.
Yahoo
5 hours ago
- Yahoo
Privia Health Group, Inc. (PRVA) Earns Top Pick Status from TD Cowen
Privia Health Group, Inc. (NASDAQ:PRVA) is among the best NASDAQ stocks under $50 to buy. Analysts at TD Cowen have named Privia Health Group, Inc. (NASDAQ:PRVA) its 'Best Smidcap Idea' while maintaining a Buy rating and a $30.00 price target. This potential surge of about 31% from the current price is driven by the company's robust financial footing, which includes zero debt and more than $400 million in cash. Over the years, Privia Health Group, Inc. (NASDAQ:PRVA) has delivered improved results, with PRVA's 17.08% year-to-date return surpassing the market's 2.58% return. The leading investment bank believes that the company possesses the potential to deliver more than 20% EBITDA growth not only in 2025 but also in 2026. This is anything but ordinary, given the current market pessimism. A physician leveraging innovative technology to enable their patient care decisions. What makes Privia Health Group, Inc. (NASDAQ:PRVA) stand out the most is its capital-light business model that yields positive free cash flow in addition to maintaining impressive EBITDA growth. The analysts believe that this is the perfect blend for the powerhouse's scalable and predictable business operation. Privia Health Group, Inc. (NASDAQ:PRVA) is a Virginia-based physician-enablement company that partners with physician practices, health plans, and health systems to provide technology and population health tools. Founded in 2007, the company also manages an accountable care organization for enhanced coordination and patient quality metrics. While we acknowledge the potential of PRVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Privia Health Group, Inc. (PRVA) Earns Top Pick Status from TD Cowen
Privia Health Group, Inc. (NASDAQ:PRVA) is among the best NASDAQ stocks under $50 to buy. Analysts at TD Cowen have named Privia Health Group, Inc. (NASDAQ:PRVA) its 'Best Smidcap Idea' while maintaining a Buy rating and a $30.00 price target. This potential surge of about 31% from the current price is driven by the company's robust financial footing, which includes zero debt and more than $400 million in cash. Over the years, Privia Health Group, Inc. (NASDAQ:PRVA) has delivered improved results, with PRVA's 17.08% year-to-date return surpassing the market's 2.58% return. The leading investment bank believes that the company possesses the potential to deliver more than 20% EBITDA growth not only in 2025 but also in 2026. This is anything but ordinary, given the current market pessimism. A physician leveraging innovative technology to enable their patient care decisions. What makes Privia Health Group, Inc. (NASDAQ:PRVA) stand out the most is its capital-light business model that yields positive free cash flow in addition to maintaining impressive EBITDA growth. The analysts believe that this is the perfect blend for the powerhouse's scalable and predictable business operation. Privia Health Group, Inc. (NASDAQ:PRVA) is a Virginia-based physician-enablement company that partners with physician practices, health plans, and health systems to provide technology and population health tools. Founded in 2007, the company also manages an accountable care organization for enhanced coordination and patient quality metrics. While we acknowledge the potential of PRVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
